HAVCR2 and hematologic disorder: An ongoing phase I clinical trial is investigating efficacy and safety of anti-Tim-3 monoclonal antibody associated with a standard-of-care, decitabine, for MDS and AML showing promising preliminary results and paving the way for its potential use in hematologic malignancies (Borate U et al., 2019; Achrya et al., 2020).